Fasting and Cancer: Does It Help During Treatment?

 

Benefits, Risks and What the Research Shows

Fasting has become an increasingly talked-about topic in the cancer space. You may have come across claims that it can “starve cancer cells”, improve the effectiveness of treatment, or reduce side effects.

There is some science behind these ideas — but as is often the case in cancer nutrition, the reality is more nuanced.

Over the past decade, researchers have explored whether fasting could play a role alongside treatments such as chemotherapy and radiotherapy. Some of the findings are promising. Others raise important questions. And when you look closely at the evidence, a more balanced picture begins to emerge.

 
 

What Is Fasting and How Is It Used in Cancer Research?

In the context of cancer research, fasting does not simply mean skipping meals or eating less over time. It typically refers to short, structured periods of little or no food intake, often timed around treatment.

Researchers have explored several approaches, including short-term fasting, longer fasting cycles, and fasting-mimicking diets — all designed to trigger specific metabolic changes.

This distinction is important. Chronic calorie restriction, where energy intake is consistently reduced, is generally not considered appropriate during cancer treatment due to the risk of weight and muscle loss (Caccialanza et al., 2022).

 

Why Is Fasting Being Studied in Cancer Treatment?

The interest in fasting stems largely from its effects on metabolism.

When the body enters a fasted state, levels of glucose, insulin and insulin-like growth factor-1 (IGF-1) begin to fall. At the same time, the body shifts towards using fat and ketones for fuel. These changes influence pathways that regulate cell growth, repair and survival.

Several mechanistic reviews suggest that this shift may create an environment that is less favourable for cancer cells, while encouraging healthy cells to enter a more protected state — a concept often referred to as differential stress resistance (Longo & Mattson, 2014; Nencioni et al., 2018).

At a theoretical level, this is compelling. But the key question is whether these effects translate into meaningful benefits in people undergoing cancer treatment.

 

What Does the Research Say About Fasting and Cancer?

Much of the strongest evidence comes from laboratory and animal studies.

Across a number of preclinical models, fasting appears to increase the sensitivity of cancer cells to treatment while protecting healthy cells from damage. Studies have shown slower tumour growth, increased cancer cell death, and improved response to chemotherapy and radiotherapy when fasting is introduced (Brandhorst & Longo, 2021; Longo & Mattson, 2014).

In some cases, combining fasting with chemotherapy has resulted in improved survival in animal models (Brandhorst & Longo, 2021).

However, this is where caution is needed.

These findings are based largely on animal studies, and while they provide valuable insight into biological mechanisms, they do not always translate into the same outcomes in humans.

 

Fasting During Chemotherapy: What Do Human Studies Show?

When fasting is studied in people undergoing chemotherapy, the findings become more measured.

Several small clinical studies have explored short-term fasting around treatment. These studies suggest that fasting may help reduce fatigue, improve tolerance to chemotherapy, and lower markers of DNA damage in healthy cells (de Groot et al., 2020; Bauersfeld et al., 2018).

Some studies have also reported improved recovery of immune cells and fewer gastrointestinal side effects (Nencioni et al., 2018).

These findings are encouraging, particularly from a quality-of-life perspective.

However, these studies are small, use different fasting protocols, and focus on short-term outcomes. They do not provide strong evidence that fasting improves long-term cancer outcomes such as recurrence or survival.

 

Fasting-Mimicking Diets and Cancer: Insights from Clinical Trials

One of the more structured approaches studied in humans is the fasting-mimicking diet (FMD).

The DIRECT trial investigated this approach in women with breast cancer undergoing chemotherapy. Participants followed a low-calorie dietary protocol for several days around each treatment cycle.

The study found improvements in tumour response on imaging, along with reductions in glucose, insulin and IGF-1, and reduced DNA damage in healthy immune cells (de Groot et al., 2020).

However, the findings were not straightforward.

There was no improvement in complete tumour response, quality of life did not significantly improve, and many participants struggled to adhere to the protocol.

This highlights an important point: measurable biological changes do not always translate into meaningful clinical outcomes.

 

Does Fasting Help Treat Cancer?

This is ultimately the question most people are asking — and the answer is not a simple yes or no.

In animal studies, fasting has shown the potential to slow tumour growth and improve response to treatment (Brandhorst & Longo, 2021). But in human studies, the evidence is far less conclusive.

The strongest and most consistent findings in patients relate to treatment tolerance — including reduced fatigue, improved side effect profiles, and lower markers of cellular damage (de Groot et al., 2020; Nencioni et al., 2018).

However, there is currently no strong clinical evidence that fasting improves tumour eradication, reduces recurrence risk, or increases survival.

A recent systematic review in breast cancer patients concluded that intermittent fasting may be feasible and safe for some individuals, but its impact on long-term outcomes remains unclear and the quality of evidence is low (D’Aronzo et al., 2023).

Observational research has suggested that longer overnight fasting may be associated with a lower risk of recurrence, but this type of data cannot establish cause and effect (Marinac et al., 2016).

Taken together, fasting may support the body during treatment — but it cannot be considered a treatment for cancer in its own right.

 

Fasting and Radiotherapy: Is It Helpful or Harmful?

The evidence becomes even more complex when fasting is considered alongside radiotherapy.

Some preclinical studies suggest fasting may enhance the effects of radiotherapy by increasing oxidative stress in cancer cells. However, clinical reviews highlight an important concern: maintaining body weight and nutritional status is critical for treatment success (Simone et al., 2021).

In this context, calorie restriction may be counterproductive, particularly if it leads to weight loss or reduced treatment tolerance and radiotherapy treatment is often administered over consecutive days. This makes it much harder to follow a stricter fasting regime.

 

Is Fasting Safe for Cancer Patients? Risks and Considerations

One of the most consistent concerns across the literature is the risk of malnutrition and muscle loss.

Many cancer patients are already vulnerable to weight loss, reduced appetite and sarcopenia. Introducing fasting in this context may worsen these issues and negatively impact treatment tolerance and recovery (Caccialanza et al., 2022).

For this reason, clinical guidance generally prioritises maintaining adequate nutrition during treatment, particularly in patients at risk.

 

Who Might Benefit from Fasting — and Who Should Avoid It?

One of the biggest gaps in the research is that we still do not know who fasting is best suited for.

Studies tend to exclude patients who are underweight or clinically vulnerable, meaning the findings apply to a relatively select group.

This makes it difficult to generalise the results, and highlights the importance of individual assessment.

 

Why Fasting Is Not a One-Size-Fits-All Approach in Cancer Care

Across all the research, one thing is clear: fasting is not a universal strategy.

Different cancers behave differently, and patients vary widely in terms of metabolic health, nutritional status and treatment response.

Even leading reviews conclude that fasting during active cancer treatment should not yet be routinely recommended outside carefully selected cases (Rock et al., 2022).

 

Can Blood Testing Help Guide Fasting in Cancer Patients?

One of the challenges with fasting is that its effects are often assumed rather than measured.

Research shows that fasting can influence markers such as glucose, insulin and IGF-1, but individual responses vary (de Groot et al., 2020; Nencioni et al., 2018).

This is where targeted blood testing can be valuable.

By assessing markers such as:

  • blood glucose and HbA1c

  • insulin

  • IGF-1

  • inflammatory markers

  • nutritional status

it becomes possible to understand how the body is responding and whether fasting is appropriate.

This allows for a more personalised and informed approach, rather than relying on generalised advice. All of these blood markers are available to my 1:1 clients via private blood testing.

Should You Try Fasting During Cancer Treatment?

The research suggests that fasting may have a role as a supportive strategy, particularly in relation to treatment tolerance and metabolic health.

However, it is not suitable for everyone, and the evidence is not strong enough to support it as a routine recommendation.

The most important question is not simply whether fasting works, but whether it is appropriate for you.

 

How to Approach Fasting Safely (and When to Get Support)

If fasting is something you are considering, it’s important to approach it with care.

In my Ultimate Fasting Guide For Cancer, I explore this in much more detail — including the different types of fasting, when it may or may not be appropriate, and how to approach it safely alongside treatment.

You can purchase my fasting guide here

 

Work With Me

If you’re unsure whether fasting is appropriate for you, this is exactly the type of decision that benefits from a personalised, evidence-led approach. Get in touch to chat about how My Cancer Nutritionist can help you.

Book a discovery call here

 

Further Reading:

  • Bauersfeld, S.P., Kessler, C.S., Wischnewsky, M., Jaensch, A., Steckhan, N., Stange, R. and Kunz, B. (2018) ‘The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: A randomized cross-over pilot study’, BMC Cancer, 18, p. 476.

  • Brandhorst, S. and Longo, V.D. (2021) ‘Fasting and caloric restriction in cancer prevention and treatment’, Recent Results in Cancer Research, 216, pp. 241–266.

  • Caccialanza, R., Laviano, A., Lobascio, F., Montagna, E., Bruno, R., Ludovisi, S., Corsico, A.G. and Cereda, E. (2022) ‘Early nutritional support in cancer patients: A position paper’, Supportive Care in Cancer, 30, pp. 3277–3289.

  • de Groot, S., Lugtenberg, R.T., Cohen, D., Welters, M.J.P., Ehsan, I., Vreeswijk, M.P.G., Smit, V.T.H.B.M., de Graaf, H., Heijns, J.B., Portielje, J.E.A., Kroep, J.R. and Pijl, H. (2020) ‘Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the DIRECT trial’, Nature Communications, 11, p. 3083.

  • D’Aronzo, M., Vinciguerra, M., Mazza, T., Panebianco, C., Saracino, C., Graziano, G., Luzza, F. and Ierardi, E. (2023) ‘Intermittent fasting and breast cancer: A systematic review’, Cancers, 15(3), p. 789.

  • Klement, R.J. and Champ, C.E. (2014) ‘Calories, carbohydrates, and cancer therapy with radiation: Exploiting the five R’s through dietary manipulation’, Cancer & Metastasis Reviews, 33, pp. 217–229.

  • Longo, V.D. and Mattson, M.P. (2014) ‘Fasting: Molecular mechanisms and clinical applications’, Cell Metabolism, 19(2), pp. 181–192.

  • Marinac, C.R., Nelson, S.H., Breen, C.I., Hartman, S.J., Natarajan, L., Pierce, J.P., Flatt, S.W. and Patterson, R.E. (2016) ‘Prolonged nightly fasting and breast cancer prognosis’, JAMA Oncology, 2(8), pp. 1049–1055.

  • Nencioni, A., Caffa, I., Cortellino, S. and Longo, V.D. (2018) ‘Fasting and cancer: Molecular mechanisms and clinical application’, Nature Reviews Cancer, 18, pp. 707–719.

  • Rock, C.L., Thomson, C.A., Sullivan, K.R., Howe, C.L., Kushi, L.H., Caan, B.J., Neuhouser, M.L., Bandera, E.V., McCullough, M.L., Gapstur, S.M. and Patel, A.V. (2022) ‘American Cancer Society guideline for diet and physical activity for cancer prevention’, CA: A Cancer Journal for Clinicians, 72(3), pp. 245–271.

  • Simone, C.B., Simone, N.L., Simone, V. and Simone, C.B. (2021) ‘Caloric restriction and fasting in radiotherapy: A review’, Radiation Oncology, 16, p. 107.

 
Next
Next

The Ultimate Cancer Fighting Food List